Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$77,840.00+1.10%ETH$2,504.38+3.44%GOLD$4,420.40+0.30%OIL$99.44-2.97%
Smart Investors Daily
Aura Biosciences, Inc. logo

NASDAQ · AURA

Aura Biosciences, Inc.

Healthcare · Biotechnology

$6.99

Down-$0.21 (-2.92%)

Updated Sep 11, 2026, 11:00 AM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
413.26M
P/E ratio
-3.72
Dividend yield
0.00%
52-week range
$5.31 – $9.54
Volume
785.54K
Avg. volume
260.47K

Price performance

AURA price history

1M range · 20 trading sessions · Daily adjusted prices

AURA closed at $6.99 after 20 trading sessions, down 8.63% for the selected period.

Last close
$6.99
Period change
-8.63%
Period low
$6.99
Period high
$8.16
Daily close
View OHLC price history
AURA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$7.14$7.195$6.93$6.99785.54K
Sep 9, 2026$7.34$7.39$7.16$7.20465.9K
Sep 8, 2026$7.48$7.56$7.28$7.36507.75K
Sep 4, 2026$7.30$7.57$7.30$7.56456.4K
Sep 3, 2026$7.58$7.635$7.26$7.37875.87K
Sep 2, 2026$7.46$7.67$7.00$7.50495.49K
Sep 1, 2026$7.11$7.515$7.11$7.43534.54K
Aug 31, 2026$7.39$7.40$7.06$7.18602.5K
Aug 28, 2026$7.66$7.79$7.36$7.40441.4K
Aug 27, 2026$7.70$7.81$7.64$7.70440.77K
Aug 26, 2026$7.76$7.78$7.60$7.73557.6K
Aug 25, 2026$7.95$8.105$7.76$7.821.13M
Aug 24, 2026$7.80$8.00$7.60$7.90843.83K
Aug 21, 2026$7.77$8.085$7.65$7.80500.88K
Aug 20, 2026$7.70$7.78$7.415$7.77643.06K
Aug 19, 2026$8.28$8.366$7.695$7.791.14M
Aug 18, 2026$7.65$8.24$7.55$8.16680.49K
Aug 17, 2026$7.71$7.82$7.55$7.683.82M
Aug 14, 2026$7.60$7.79$7.455$7.69684.97K
Aug 13, 2026$7.635$8.00$7.445$7.651.05M

Latest AURA news

The latest Smart Investors Daily articles mentioning AURA.

Stock researchCompany · Overview

AURA research

Overview

Company profile and research snapshot.

Company profile

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$22.75
Implied upside
—
Analysts
—
AURA recent ratings
DateFirmRatingTarget
Aug 11, 2026HC Wainwright & Co.Buy—
Apr 29, 2026HC Wainwright & Co.Buy—
Mar 30, 2026HC Wainwright & Co.Buy—
Nov 26, 2025Evercore ISI GroupOutperform—
Aug 13, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 6, 2026

Is Aura Investments (TASE:AURA) Fully Valued As Mixed Earnings And A New Dividend Stir Interest?

How Aura Investments Stock Is Reacting To Mixed Earnings And A New Dividend Aura Investments (TASE:AURA) has drawn fresh attention after second quarter and half year results showed higher revenue alongside lower net income and earnings per share, paired with a recently updated cash dividend announcement. At a share price of ₪19.7, Aura Investments has seen a 34.29% 1 month share price return and 11.05% 7 day share price return following the earnings and dividend updates, while the share price...

Yahoo · Sep 2, 2026

Aura Biosciences to Participate in Upcoming Investor Conference

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference: Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026.Fireside Chat at 2:35 p.m. ET The live webcast of the fireside chat will

Yahoo · Sep 1, 2026

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Erica Kratz, Ph.D., Aura’s new Chief Regulatory and Quality Officer, Susan Abu-Absi, Ph.D., Aura’s new Chief Operating Officer, and Julie Person, Aura’s new C

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By